Healthcare refers to the field associated with maintaining or restoring patients’ health. These days’ Healthcare Industry falls into a lashing of discrete sub-sectors, and ancillary goods and services. Ranging from therapeutic equipment to medicinal drugs, medical tourism to sickness insurance, the Healthcare Market has been one of the most swiftly expanding sectors within the globe’s economic system.
Global Healthcare spending contributes close to 10% to the whole world’s GDP, though it varies noticeably with geography. Thus, the Western world’s average healthcare costs are far greater in contrast to those in the developing economies. North America alone is in charge of circa a half of the world’s overall spending on healthcare services. With budgets curtailments and growing costs, technology advances are increasingly taking a new meaning in the global Healthcare universe.
The research reports offer comprehensive insights into the market sizing, structure and dynamics of the Healthcare Industry based on various geographies, as well as in-depth market segmentation. The research reports incorporated in this Catalogue closely investigate the competition in the Healthcare Market, besides profiling countless market participants. Moreover, tomorrow's healthcare-related challenges are addressed, as well as projections into the future are provided in the research reports.
Publications found:
68,523
Sort by:
Neuroendocrine Tumors - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
692 pages
Recurrent Malignant Glioma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
62 pages
Hyperglycemia - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Hyperglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
31 pages
Keloids - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
55 pages
Small-Cell Lung Cancer - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
1225 pages
Activin Receptor Type 1 - Pipeline Review, H2 2019
US$ 3,500.00
... releases. The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
75 pages
High-Grade Glioma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
568 pages
Western Equine Encephalitis - Pipeline Review, H2 2019
US$ 2,000.00
... . The Western Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Western Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
33 pages
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Mucopolysaccharidosis I (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
106 pages
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2019
US$ 2,000.00
... Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under ...
December 2019
58 pages
Sicca Syndrome (Sjogren) - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
173 pages
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2019
US$ 3,500.00
... Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
84 pages
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2019
US$ 3,500.00
... Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
156 pages
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019
US$ 3,500.00
... Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
88 pages
Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2019
US$ 2,000.00
... . The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
127 pages
Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2019
US$ 3,500.00
... Cell Division Protein FtsZ (ftsz) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
34 pages
Dystrophin (DMD) - Pipeline Review, H2 2019
US$ 3,500.00
... reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
117 pages
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2019
US$ 3,500.00
... Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
51 pages
Adenosine Receptor A3 (ADORA3) - Pipeline Review, H2 2019
US$ 3,500.00
... Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
76 pages
Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019
US$ 3,500.00
... Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
81 pages
Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019
US$ 3,500.00
... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape Develop and design in-licensing and ...
December 2019
34 pages
Radiodermatitis - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
49 pages
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2019
US$ 3,500.00
... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape Develop and design in-licensing and ...
December 2019
67 pages
Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019
US$ 3,500.00
... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape Develop and design in-licensing and ...
December 2019
78 pages
Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
118 pages
Meningioma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
349 pages
Hemochromatosis - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
45 pages
Vulvar Cancer - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
243 pages
Familial Amyloid Neuropathies - Pipeline Review, H2 2019
US$ 2,000.00
... . The Familial Amyloid Neuropathies (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
102 pages
Graves' Ophthalmopathy - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
77 pages
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
303 pages
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
66 pages
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Mucopolysaccharidosis III (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
98 pages
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
December 2019
40 pages
Rhino-Conjunctivitis - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Rhino-Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
74 pages
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019
US$ 3,500.00
... Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
104 pages
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development ...
December 2019
146 pages
Bullous Pemphigoid - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
120 pages
DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019
US$ 3,500.00
... DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
December 2019
35 pages
Gaucher Disease - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Gaucher Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
95 pages
Heart Transplant Rejection - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Heart Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
35 pages
Hyperinsulinemia - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Hyperinsulinemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperinsulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
73 pages
Merkel Cell Carcinoma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
599 pages
Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
81 pages
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H2 2019
US$ 2,000.00
... . The Neurofibromatoses Type I (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
63 pages
Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ornithine-Transcarbamylase Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
45 pages
Presbyopia - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
December 2019
49 pages
Usher Syndrome - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
December 2019
55 pages
